In Section C, individuals will obtain ABBV-744 and oral navitoclax. In Segment D, individuals will receive ABBV-744 and ruxolitinib. Participants will receive treatment until eventually disease progression or the participants are unable to tolerate the study drugs. - "Our study discovered the vital role on the KLF16/MYC regulatory axis in https://davidn776zkv9.frewwebs.com/profile